James E. Dentzer
Known title: DirectorCIK: 0001400977
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Curis shares not highlighted in recent premarket movers list. Recent market reports listing top premarket movers did not include Curis, focusing instead on other stocks like Veea. The absence from this specific list indicates no major immediate news catalyst was reported for the company in that context. The stock remains in a low RSI zone, suggesting recent selling pressure, but no new fundamental changes were detailed in the provided sources.
Transaction History
| IMNN | ▲ Buy | Grant | 6,934 | $11K | 7/31/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 11,148 | $25K | 5/22/2026 | View on chart |
| CRIS | ▼ Sell | Other | 133,333 | — | 3/20/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 3,318 | $31K | 8/4/2025 | View on chart |
| CRIS | ▼ Sell | Open Market | 3,094 | $9K | 1/31/2022 | View on chart |
| CRIS | ▼ Sell | Open Market | 2,406 | $8K | 1/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Imunon Shares Debt Conversion and Ovarian Cancer Data
Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.
Imunon Shares Debt Conversion and Ovarian Cancer Data. Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.